In three types of @entity99 , 32 hemoperfusions over polyhema-coated Amberlite XAD-2 resin were performed. An attack of acute intermittent @entity6050 subsided after a 6-h hemoperfusion. During the procedure, 13 L of plasma was completely cleared of @entity7889 . In a @entity1 with variegate @entity6050 , the laboratory changes were slight and no clinical effect of hemoperfusion was seen. In a @entity1 suffering from @entity6050 @entity10921 resistant to standard therapy, 30 hemoperfusions were performed during a period of 10 months. The total plasma @entity7170 concentration increased sharply following the start of the treatment, and preceding the fifth procedure it reached a peak of four times the initial value. Since then, the plasma @entity7170 level decreased, eventually to one-half the starting value. The mean drop in @entity7170 level during each perfusion was 22%. Similar changes were observed in the amount of @entity7889 excreted into the urine, which, following an early rise, decreased to 25% of the initial value. However, the @entity1 's skin vulnerability improved only slightly. There were no untoward effects of the treatment.

Resin hemoperfusion in XXXX .

@entity1 :: ('9606', 'Species') :: ['patient', 'child'] @entity10921 :: ('MESH:D017119', 'Disease') :: ['cutanea tarda'] @entity7889 :: ('MESH:D011166', 'Chemical') :: ['porphyrins'] @entity7170 :: ('CHEBI:8337', 'Chemical') :: ['porphyrin'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic porphyrias'] @entity6050 :: ('MESH:D011164', 'Disease') :: ['porphyria']
@entity99 :: (MESH:D056486,Disease) :: ['hepatic porphyrias']
